目的 選擇合適的方法評(píng)價(jià)抗程序性死亡受體1（PD-1）單克隆抗體在體外引起細(xì)胞因子釋放的風(fēng)險(xiǎn)。方法 通過抗體與人PBMC細(xì)胞共培養(yǎng)6、24 h，并用流式技術(shù)評(píng)估重組人源化抗PD-1單克隆抗體（F520）和已上市抗PD-1單克隆抗體Opdivo、Keytruda是否存在引起細(xì)胞因子釋放綜合征（cytokine release syndrome，CRS）的風(fēng)險(xiǎn)。結(jié)果 成功建立了采用人PBMC細(xì)胞在體外進(jìn)行抗PD-1單克隆抗體細(xì)胞因子釋放的評(píng)價(jià)技術(shù)。結(jié)論 與人PBMC細(xì)胞的共培養(yǎng)6、24 h，F(xiàn)520、Opdivo和Keytruda在體外均不存在引起CRS的風(fēng)險(xiǎn)。

Objective Choose the appropriate method to evaluate cytokine release syndrome induced by anti-PD1 monoclonal antibody in vitro. Methods PBMC Cells were cocultured with mAb for 6 and 24 hours. Using FACS, we evaluated the risk of cytokine release syndrome induced by F520, Opdivo and Keytruda.Results Successfully established the method to evaluate cytokine release syndrome induced by anti-PD1 monoclonal antibody in vitro.Conclusion Cocultured with PBMC Cells for 6 and 24 hours, the results strongly emphasized that F520, Opdivo and Keytruda could not induce cytokine release syndrome.